Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK ...
The Malaysian Reserve

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Heal…

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Targeted Oncology

Phase 3 TROPION-Lung17 Trial Initiates TROP2-Directed Therapy in NSCLC

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

Zymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) ...
National Law Review

Federal Circuit Strikes Life Sciences Patent Over Insufficient Disclosure of Particular Species

The Federal Circuit held that general disclosure of any part of a compound may be insufficient to support a priority date for ...